Research and Development

Research and Development

Patent portfolio

Biomarker portfolio

  1. “Prognostic and Diagnostic Glycan-based Biomarkers of Brain Damage” Granted European Patent No. 3283880, US Patent No. 10,739,335, Canada and Israel allowable (patent number pending)
  2. “Non-invasive brain injury diagnostic device” PCT-application WO2018154401, has entered into national phases,
    Utility model granted in China and Australia
  3. ”Device and method for detecting of brain injury in a subject” PCT-application No. PCT/FI2020/050719

  4. ”A method for determining a lectin binding glycan indicative to traumatic brain injury” PCT-application No. PCT/FI2021/050091



NCE portfolio

  1. ”Multivalent compounds for use in the treatment and prevention of brain damage" US patent No. 9,975,846, Finnish patent No. 127 024, Israeli patent No. 251 407, European patent No. 3201173
  2. ”Compositions, and compositions for use in preventing or treating of brain damage and neurodegenerative diseases” PCT-application No. PCT/FI2020/050533